B001 for NMOSD: reducing relapses
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD (neuromyelitis optica spectrum disorder).
- You have had at least 1 relapse in the past year, or at least 2 relapses in the past 2 years.
- You are not pregnant or breastfeeding, and you agree to use birth control during the study and for 6 months after.
- You have not received certain treatments (like anti-CD20 drugs) in the last 6 months.
- You are willing to follow the study plan and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
This study uses MRI scans to look for hidden disease activity in people with NMOSD who feel stable and are already on rituximab. The goal is to catch any signs of damage early, which might help prevent future disability.
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
This trial tests whether an investigational drug called KSVCBD can safely reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). If you have had at least one relapse in the past year and meet other criteria, you may be able to join.
Hear when a new Neuromyelitis Optica Spectrum Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.